SEC Form 4 · accession 0000899243-17-007645
KERYX BIOPHARMACEUTICALS INC · KERX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Greg Madison
Officer — President and CEO · Director
Period of report
Feb 14, 2017
Accepted (ET)
Mar 15, 2017 · 6:26 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001114220
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Feb 14, 2017 | A | 150,000 | $0.00 | A | 383,711 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F3 | $5.53 | Feb 14, 2017 | A | 300,000 | A | Feb 14, 2018 | Feb 14, 2027 | Common Stock | 300,000 | 300,000 | D |
Explanation of responses
- F1The 150,000 shares are restricted common stock, with one-third of the 150,000 shares vesting on February 14, 2018 and one-twelfth vesting on each of May 14, 2018, August 14, 2018, November 14, 2018, February 14, 2019, May 14, 2019, August 14, 2019, November 14, 2019 and February 14, 2020.
- F2Includes 263,790 shares of restricted stock.
- F3The options vest according to the following schedule: one-third of the 300,000 options will vest on February 14, 2018 and one-twelfth will vest on each of May 14, 2018, August 14, 2018, November 14, 2018, February 14, 2019, May 14, 2019, August 14, 2019, November 14, 2019 and February 14, 2020.